Frontiers in Pharmacology · 2016 · 45 citations · 14 references
Life SciencesInfectious DiseasesPharmacologyInflammationInnate ImmunityMucosal ImmunologyBacterial ToxinsGastrointestinal InflammationGastrointestinal ToxicityInflammatory SignalingMucosal InflammationToxin-mediated DiseaseCaco-2 Cell AssayClostridioides Difficile Infection TreatmentColonic UlcerationDrug-induced Mucosal InjuryEnterotoxin-mediated DiseaseTherapeutic Toxin ApplicationsToxin-induced InflammationToxin-mediated Mucosal Injury
BACKGROUND: Clostridium difficile infections (CDIs) caused by Clostridium difficile toxin A (TcdA) lead to severe ulceration, inflammation and bleeding of the colon, and are difficult to treat. AIM: The study aimed to evaluate the effect of rifaximin on TcdA-induced apoptosis in intestinal epithelial cells and investigate the role of PXR in its mechanism of action. METHODS: Caco-2 cells were incubated with TcdA and treated with rifaximin (0.1-10 μM) with or without ketoconazole (10 μM). The transepithelial electrical resistance (TEER) and viability of the treated cells was determined. Also, the expression of zona occludens-1 (ZO-1), toll-like receptor 4 (TLR4), Bcl-2-associated X protein (Bax), transforming growth factor-β-activated kinase-1 (TAK1), myeloid differentiation factor 88 (MyD88), and nuclear factor-kappaB (NF-κB) was determined. RESULTS: Rifaximin treatment (0.1, 1.0, and 10 μM) caused a significant and concentration-dependent increase in the TEER of Caco-2 cells (360, 480, and 680% vs. TcdA treatment) 24 h after the treatment and improved their viability (61, 79, and 105%). Treatment also concentration-dependently decreased the expression of Bax protein (-29, -65, and -77%) and increased the expression of ZO-1 (25, 54, and 87%) and occludin (71, 114, and 262%) versus TcdA treatment. The expression of TLR4 (-33, -50, and -75%), MyD88 (-29, -60, and -81%) and TAK1 (-37, -63, and -79%) were also reduced with rifaximin versus TcdA treatment. Ketoconazole treatment inhibited these effects. CONCLUSION: Rifaximin improved TcdA-induced toxicity in Caco-2 cells by the PXR-dependent TLR4/MyD88/NF-κB pathway mechanism, and may be useful in the treatment of CDIs.
14
Essential function for the kinase TAK1 in innate and adaptive immune responses
Shintaro Sato, Hideki Sanjo, Kiyoshi Takeda et al. · Nature Immunology · 2005 · 968 citations